| Indication | Duchenne muscular dystrophy (DMD) cardiomyopathy |
| Drug | deramiocel |
| Mechanism of Action | cell therapy |
| Company | Capricor Therapeutics |
| Trial Phase | Phase 3 |
| Trial Acronym | HOPE-3 |
| Category | Regulatory Milestone |
| Sub Category | Advisory Committee (AdCom) Meeting |
| Therapeutic Area | Rare Diseases & Genetics |
| Regulatory Agency | FDA |
| Advisory Committee | Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) |
| Vote Outcome (deramiocel) | 9-3 against recommendation |
| Vote Outcome (RP1) | 10-3 in favor of approval |
| PDUFA Date (RP1) | August 2 |
| Combination Partner (RP1) | Bristol Myers Squibb’s Opdivo |
| Patient Population (deramiocel) | Duchenne muscular dystrophy cardiomyopathy |
| Patient Population (RP1) | Advanced melanoma |
| Trial Design Issue (RP1) | Contribution of effect not demonstrated, data "not interpretable" |
| Legal Action Consideration | Capricor CEO Linda Marbán |
FDA Advisory Committees Create Confusion for Rare Disease Therapies
The FDA's recent advisory committee meetings for Capricor Therapeutics' deramiocel and Replimune's RP1 have created significant confusion and frustration, challenging the agency's efforts to rebuild trust in the rare disease sector. Capricor's deramiocel, a cell therapy for Duchenne muscular dystrophy cardiomyopathy, faced a 9-3 negative vote from the CTGTAC, prompting its CEO to consider legal action over the statistical analysis of the Phase 3 HOPE-3 trial. Conversely, Replimune's RP1 for advanced melanoma received a 10-3 positive vote, but the FDA's decision date of August 2 has passed without an announcement, leaving the company and patients in an "indeterminate limbo." These events raise questions about the FDA's transparency and consistency, particularly after previous reversals of decisions for other rare disease therapies.
- The FDA's attempts to restore industry trust, especially in rare diseases, following the departure of former Commissioner Marty Makary, appear jeopardized by recent advisory committee meetings. While earlier decisions saw reversals for uniQure's Huntington's disease gene therapy and REGENXBIO's Hunter syndrome gene therapy, the outcomes for Capricor and Replimune suggest ongoing regulatory turbulence, raising doubts about the agency's commitment to transparency and consistent guidance.
- Capricor Therapeutics' deramiocel, a cell therapy for Duchenne muscular dystrophy cardiomyopathy, was met with a 9-3 negative vote from the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) for approval. The FDA's presentation and statistical analysis of the Phase 3 HOPE-3 trial were heavily criticized by the company and patient advocates, with Capricor's CEO, Linda Marbán, expressing shock and indicating a willingness to pursue legal action due to perceived "ulterior motives" and misalignment on data interpretation.
- Replimune's RP1, an immunotherapy for advanced melanoma in combination with Bristol Myers Squibb’s Opdivo, secured a favorable 10-3 vote from the CTGTAC. However, the FDA's PDUFA date of August 2 has passed without a decision, leaving the company and the medical community in uncertainty. The FDA had previously raised concerns about the trial's interpretability and the individual contribution of RP1's effect, suggesting a potential third Complete Response Letter despite the adcomm's recommendation.
Addressing Critical Unmet Needs in DMD Cardiomyopathy
Cardiomyopathy is a leading cause of mortality in Duchenne muscular dystrophy (DMD), yet significant gaps persist in its management. Addressing these challenges is critical for improving long-term outcomes, with a focus on better prediction of disease progression, identification of new therapeutic targets, and optimization of care for specific patient populations.
Predicting Disease Onset and Progression: A critical need exists for reliable methods and biomarkers to predict the onset and highly variable progression rate of DMD-associated cardiomyopathy. No clear genotype-phenotype correspondence for cardiac involvement has been established, making it difficult to anticipate which patients will experience rapid decline. Improved techniques, such as advanced imaging and deep learning algorithms, are required to track progression, define robust clinical trial endpoints, and optimize treatment timing.
Understanding Genetic Modifiers: Research is needed to identify genetic factors beyond the primary dystrophin mutation that modulate cardiac disease. Assessing the genetic origin of phenotypic variability—and evaluating genes implicated in primary cardiomyopathies—could help elucidate pathogenic mechanisms and provide prognostic insights for better patient management.
Expanding Access to Advanced Cardiac Therapies: Individuals with DMD and advanced heart failure are rarely considered for life-prolonging interventions like ventricular assist devices (VADs) and heart transplantation. Overcoming the clinical challenges and institutional barriers that have historically excluded this population is a major unmet need, especially as standard heart failure treatments remain unsatisfactory.
Targeting Early and Genotype-Specific Disease: Clinical data highlights the need to target specific patient subgroups for earlier intervention. Early cardiac involvement, including autonomic dysfunction, has been detected in young, ambulant patients (ages 5–10) before the onset of dilated cardiomyopathy. Furthermore, patients with proximal mutations (exons 1-44) exhibit more cardiac dysfunction than those with distal mutations, suggesting a need for genotype-specific monitoring strategies.
Improving Assessment Tools and Standardizing Care: Standard heart failure assessments, such as ejection fraction and symptomatology, have limitations in the DMD population. There is a need to integrate alternative evaluation tools like cardiac MRI, biomarkers, and adapted exercise testing. A standardized framework for the initiation and optimization of cardiac medications is also required to reduce care variability and improve outcomes.
Frequently Asked Questions
References
- [1] Yuan C, Hamm SE et al.. Voluntary running sustains the correction of inflammation-related gene expression conferred by AAV gene therapy in mdx mice. Molecular therapy. Advances. 2026 Mar 12. 42137295
- [2] Esteso P, Auerbach SR et al.. Cardiac treatment for Duchenne muscular dystrophy: consensus recommendations from the ACTION muscular dystrophy committee. Cardiology in the young. 2025 Apr. 40012319
- [3] Broomfield J, Abrams K et al.. Natural history of Duchenne muscular dystrophy in the United Kingdom: A descriptive study using the Clinical Practice Research Datalink. Brain and behavior. 2023 Dec. 37957895
- [4] Tang A, Yokota T. Brogidirsen and Exon 44 Skipping for Duchenne Muscular Dystrophy: Advances and Challenges in RNA-Based Therapy. Genes. 2025 Jun 30. 40725431
- [5] Argiro A, Bui Q et al.. Applications of Gene Therapy in Cardiomyopathies. JACC. Heart failure. 2024 Feb. 37966402
- [6] Lava SAG, Laurence C et al.. Repurposing Empagliflozin for Duchenne Muscular Dystrophy-Associated Cardiomyopathy: Protocol for a Pharmacokinetics, Safety and Proof-of-Concept Trial in Children. Cardiology and therapy. 2026 May 30. 42223801
- [7] Earl CC, Soslow JH et al.. Myocardial strain imaging in Duchenne muscular dystrophy. Frontiers in cardiovascular medicine. 2022. 36505382
- [8] Andrews JG, Heikke BL et al.. Changes in Provision of Recommended Cardiac Care for Duchenne Muscular Dystrophy Using a Longitudinal Cohort. Muscle & nerve. 2026 Aug. 42157332
- [9] Horn S, Fehse B. [How safe is gene therapy? : Second death after Duchenne therapy]. Innere Medizin (Heidelberg, Germany). 2024 Jun. 38748280
- [10] Cho A. Neuromuscular diseases: genomics-driven advances. Genomics & informatics. 2024 Nov 26. 39593150
- [11] Vincik LY, Dautel AD et al.. Evolving Role of Viltolarsen for Treatment of Duchenne Muscular Dystrophy. Advances in therapy. 2024 Apr. 38376743
- [12] Antonello BB, Cargnelutti Fontoura F et al.. Duchenne Muscular Dystrophy and Delandistrogene Moxeparvovec Gene Therapy in Children: A Systematic Review and Meta-Analysis. Neurology. Genetics. 2026 Aug. 42396397
- [13] Hammers DW, Hart CC et al.. Combination S100A1 and ARC gene therapy as a treatment for DMD cardiomyopathy. JCI insight. 2026 Jun 9. 42262882
- [14] Komaki H. Duchenne muscular dystrophy: Evolving therapeutic strategies and multidimensional evaluation approaches. Brain & development. 2025 Oct. 40712356
- [15] Khan G, Hussain MS. Expanding the Potential of Gene Therapy for Duchenne Muscular Dystrophy. Current pharmaceutical design. 2026. 40357789
- [16] Shashikala, Haider S et al.. Unravelling the Complications of Dilated Cardiomyopathy in Duchenne Muscular Dystrophy: From Molecular Pathways to Disease Management. Cardiovascular & hematological disorders drug targets. 2026. 41508970
- [17] Hollander SA, Rosenthal D. Meeting report: Expanding access to advanced cardiac therapies, including ventricular assist devices (VADs) and heart transplantation in muscular dystrophy. Neuromuscular disorders : NMD. 2026 Mar. 41581379
- [18] Cope H, Fischer R et al.. Clinician Perspectives of Gene Therapy as a Treatment Option for Duchenne Muscular Dystrophy. Journal of neuromuscular diseases. 2024. 39093077
- [19] McDonald C, Camino E et al.. Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies - Developing Potential Treatments for the Entire Spectrum of Disease. Journal of neuromuscular diseases. 2024. 38363616
- [20] Kaynak E, Eroğlu AG et al.. Could N-terminal pro-brain natriuretic peptide predict cardiac involvement in children with Duchenne muscular dystrophy as detected by real-time three-dimensional (four-dimensional) and speckle-tracking echocardiography?. Cardiology in the young. 2026 Apr 10. 41958305
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
